Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
ZYMAR is an ophthalmic antibiotic solution approved in 2003 for bacterial eye infections. It is administered as topical eye drops and represents a small-molecule therapeutic in the ophthalmology space. The drug treats patients with bacterial conjunctivitis and other external ocular infections.
Product approaching loss of exclusivity with moderate competitive pressure (30%), signaling potential team downsizing or strategic repositioning initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Effectiveness Study of Zymar Versus Vigamox for Preoperative Sterilization of the Ocular Surface After Loading Dose
Working on ZYMAR offers limited career advancement given zero linked job postings and approaching LOE status. Roles are primarily transactional (sales, brand management) with focus on defending market share against generics rather than driving growth.
Worked on ZYMAR at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.